Medicine supply management

AI Summary

The Department of Health and Social Care (DHSC) and NHS England oversee the management of medicine supply chains across the United Kingdom. This guidance outlines the framework for mitigating disruptions caused by issues such as raw material shortages, packaging delays, and regulatory compliance testing. Under current regulations, manufacturers have a legal obligation to report any potential medicine shortages or discontinuations through the Discontinuations and Shortages (DaSH) portal. While DHSC holds strategic responsibility for England, it coordinates closely with the Medicines and Healthcare products Regulatory Agency (MHRA) and devolved governments to ensure equitable access to medications nationwide. When a supply issue is identified, DHSC and NHS England assess its impact alongside industry partners. Management strategies include issuing Medicine Supply Notifications (MSNs) to healthcare professionals and utilizing the NHS medicines supply tool. In significant cases, Serious Shortage Protocols (SSPs) allow pharmacists to provide alternative medications without a new prescription. Additionally, the MHRA may issue National Patient Safety Alerts for complex shortages. The guidance emphasizes that companies must adhere to export and hoarding restrictions to maintain domestic supply. While specific inspection dates and company-specific violations are not detailed in this general policy document, the framework establishes a mandatory reporting system to prevent patient harm. Manufacturers are encouraged to consult MHRA guidelines on regulatory processes designed to ease supply pressures.